PhD Scientific Days 2023

Budapest, 22-23 June 2023

Clinical Medicine - Posters A

Non-progressors to cardiac resynchronization therapy show long-term mortality benefit compared to progressors

Anett Behon, M.D. 1
Eperke Dóra Merkel, M.D. 1
Walter Richard Schwertner, M.D. 1
Luca Katalin Kuthi, M.D. 1
Boglárka Veres, M.D. 1
Richard Masszi M.D. 1
Attila Kovács, M.D., Ph.D. 1
Bálint Károly Lakatos, M.D., Ph.D. 1
Endre Zima, M.D., Ph.D., D.Sc. 1
László Gellér, M.D., Ph.D., D.Sc. 1
Annamária Kosztin, M.D., Ph.D. 1
Béla Merkely, M.D., Ph.D., D.Sc. 1
1 Semmelweis University, Heart and Vascular Center, Budapest, Hungary

Text of the abstract

Introduction: Approximately one-third of patients undergoing cardiac resynchronization therapy (CRT) implantation fail to show clinical improvement or reverse remodeling. The criteria by response have recently changed: patients with a minimal improvement in left ventricular ejection fraction (LVEF) are defined as “non-progressors” rather than “non-responders”, selecting from those patients in whom the progression could not be modified. Data are scarce regarding the long-term outcome of this patient population.
Aims: We aimed to evaluate the long-term outcome of CRT patients by their response status.
Method: Altogether 1019 patients undergoing CRT implantation between 2000-2020 in our center were registered and analyzed retrospectively. Patients were divided into 4 groups according to their response status, which was defined on the basis of LVEF change in 12 months after CRT implantation as follows: super-responders ≥20% (n=113), responders 6-19% (n=448), non-progressors 0-5% (n=244), and progressors <0% (n=214). The primary endpoint was the composite of all-cause mortality, heart transplantation, or left ventricular assist device implantation.
Results: During the median follow-up time of 4.7 years 547 (54%) patients died, 35 (31%) super-responders, 223 (50%) responders, 133 (55%) non-progressors, and 156 (73%) progressors. The mean change in LVEF occurred as follows: super-responders 24.5% ± 4.1%, responders 11.5% ± 3.8%, non-progressors 2.8% ± 1.8%, and progressors -6.6% ± 4.5% (p<0.01). Univariate Cox regression analysis revealed that non-progressors had a similar outcome to responders (HR 1.17; 95%CI 0.94-1.45; p=0.15) and a superior outcome to progressors (HR 0.60; 95%CI 0.48-0.76; p<0.01), which was also confirmed by multivariate analysis: non-progressors vs. responders (HR 1.25; 95%CI 0.98-1.58; p=0.07) and non-progressors vs. progressors (HR 0.62; 95%CI 0.47-0.80; p<0.01).
Conclusion: In our current study, non-progressors to CRT had a similar long-term outcome to responders and superior outcome to progressors. These findings suggest that non-progressor patients would have continued to adversely remodel without CRT and CRT is beneficial for these patients by moderating the remodeling process rather than improving it. Our results support the fact that patients could be grouped as super-responders, responders, non-progressors, and progressors.
Funding: The research was supported by the Semmelweis 250+ Excellence Ph.D. Scholarship (EFOP-3.6.3-VEKOP-16-2017-00009).